Busetto, Luca http://orcid.org/0000-0003-4883-8980
Carbonelli, Maria Grazia
Caretto, Antonio
Colao, Annamaria
Cricelli, Claudio
De Luca, Maurizio
Giorgino, Francesco
Gnessi, Lucio
Medea, Gerardo
Pappagallo, Giovanni
Santini, Ferruccio
Sbraccia, Paolo
Zappa, Marco Antonio
Funding for this research was provided by:
Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement.
Article History
Received: 28 February 2022
Accepted: 2 April 2022
First Online: 17 May 2022
Declarations
:
: LB reports Advisory Boards: Novo Nordisk. Speaker: Bruno Farmaceutici and Therasience; FG reports Advisory Boards: AstraZeneca; Eli Lilly; Novo Nordisk; Roche Diabetes Care, Sanofi. Consultant: Boehringer Ingelheim; Lifescan; Merck Sharp & Dohme; Sanofi, AstraZeneca, Medimmune, Roche Diabetes Care, Sanofi, Medtronic. Research support: Eli Lilly, Roche Diabetes Care; FS has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with obesity and related diseases: AstraZeneca, Aegerion Pharmaceuticals, Fujirebio, Pfizer, Amryt, BioItalia, Bruno farmaceutici, Damor pharmaceuticals and Novo Nordisk, GM reports Roche Diagnostici. The remaining authors have no competing interests to declare that are relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.